Effect of recombinant erythropoietin on λate" transfusions in the neonatal intensive care unit: A meta-analysis

被引：34

作者：

Garcia M.G. ^{[1
,2
]}

Hutson A.D. ^{[2
]}

Christensen R.D. ^{[3
]}

机构：

[1] The National Institute of Perinatology, Mexico City

[2] The Department of Pediatrics, Division of Neonatology, Division of Biostatistics, Department of Statistics, University of Florida College of Medicine, Gainesville, FL

[3] The Department of Pediatrics, University of South Florida and All Children’s Hospital, St. Petersburg, FL

来源：

Journal of Perinatology | 2002年 / 22卷 / 2期

关键词：

D O I：

10.1038/sj.jp.7210677

中图分类号：

学科分类号：

摘要：

Objectives: Using the approach of a meta-analysis, we sought to determine whether the administration of recombinant erythropoietin (rEpo) to very low birth weight (VLBW) infants, after the first week of life, results in fewer "late" transfusions. Study Design and Methods: The guidelines set forth by the Cochrane Neonatal Review Group were used to identify all relevant studies. Medline was searched from January 1990 to November of 2000. Studies that used a randomized, placebo-controlled, and double-masked design were deemed acceptable. Results: Eight studies meet the inclusion criteria. These involved 357 VLBW neonates: 183 rEpo and 174 placebo recipients. The neonates in the rEpo group received fewer erythrocyte transfusions during the study period than did those in the placebo group; the common odds ratio (OR) = 0.33; 95% confidence interval (CI) 0.21-0.51. Furthermore, the rEpo effect size was a function of the dose of rEpo administered (p = 0.0001). Conclusion: A meta-analysis of the most scientifically rigorous studies on this topic indicates that administration of rEpo to VLBW infants reduces "late" erythrocyte transfusions in a dose-dependent manner.

引用

页码：108 / 111

页数：3

共 23 条

[1] Ohls R.K., The use of erythropoietin in neonates, Clin. Perinatol., 27, pp. 681-696, (2000)
[2] Ohls R.K., Erythropoietin to prevent and treat the anemia of prematurity, Curr. Opin. Pediatr., 11, pp. 108-114, (1999)
[3] Juul S.E., Erythropoietin in the neonate, Curr. Prob. Pediatr., 29, pp. 133-149, (1999)
[4] Cazzola M., Mercuriali F., Brugnara C., Use of recombinant human erthropoietin outside the setting of uremia, Blood, 89, pp. 4248-4267, (1997)
[5] Meyer M.P., Anaemia of prematurity. Epidemiology, management and costs, Pharmacoeconomics, 12, pp. 438-445, (1997)
[6] Vamvakas E.C., Strauss R.G., Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity, Transfusion, 41, pp. 406-415, (2001)
[7] Mulrow C.D., Oxman A.D., 1996 Cochrane Collaborative Handbook, 3
[8] Shannon K., Mentzer W., Abels R., Et al., Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study, J. Pediatr., 118, pp. 949-955, (1991)
[9] Shannon K., Mentzer W., Abels R., Et al., Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: A pilot study, J. Pediatr., 120, pp. 586-592, (1992)
[10] Emmerson A., Coles H., Stern C., Pearson T., Double blind trial of recombinant human erythropoietin in preterm infants, Arch. Dis. Child., 68, pp. 291-296, (1993)

← 1 2 3 →